IL5 and breast carcinoma: Importantly, Th2 cell immunity, facilitated by the release of interleukin 3 (IL-3), interleukin 5 (IL-5), and granulocyte-macrophage colony-stimulating factor (GM-CSF), induces terminal differentiation in developing breast cancer.